EP0944403A2 - Hydrogel ameliore pour la creation de tissu - Google Patents

Hydrogel ameliore pour la creation de tissu

Info

Publication number
EP0944403A2
EP0944403A2 EP97953182A EP97953182A EP0944403A2 EP 0944403 A2 EP0944403 A2 EP 0944403A2 EP 97953182 A EP97953182 A EP 97953182A EP 97953182 A EP97953182 A EP 97953182A EP 0944403 A2 EP0944403 A2 EP 0944403A2
Authority
EP
European Patent Office
Prior art keywords
hydrogel
composition
alginate
soluble salt
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97953182A
Other languages
German (de)
English (en)
Inventor
Kermit M. Borland
Tao Zhou
Gordon P. Nelson
Daniel R. Omstead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theramat Inc
Original Assignee
Reprogenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reprogenesis Inc filed Critical Reprogenesis Inc
Publication of EP0944403A2 publication Critical patent/EP0944403A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids

Definitions

  • the present invention is directed to a process of implanting a suspension of cells and/or hydrogel particles for the creation of new tissue in vivo.
  • Contour deformities whether traumatic, congenital, or aesthetic, currently require invasive surgical techniques for correction. Furthermore, deformities requiring augmentation often necessitate the use of alloplastic prostheses which suffer from problems of infection and extrusion.
  • Collagen paste has been used to produce tissue bulk in certain application (e.g. 'Contigen' used to correct mtrinsic Sphincter Deficiency Incontinence), as has Teflon® paste (vesicoureteral reflux, vocal cord paralysis).
  • collagen has been shown to degrade rapidly (6- 12 months) in vivo, requiring multiple treatments to maintain bulk, and it is therefore unsatisfactory for correction of, e.g., craniofacial deformities.
  • alginate in other formulations has been shown to degrade in only months in vivo. Teflon paste particles have been demonstrated to migrate from the injection site, perhaps preferentially to the brain.
  • Tissue engineering involves the morphogenesis of new tissues from constructs formed of isolated cells and biocompatible polymers. Cells can be adhered onto a polymeric matrix and implanted to form a cartilaginous structure. This can be accomplished, as described in U.S. Patent No. 5,041,138 to Vacanti, et al., by shaping of the matrix prior to implantation to form a desired anatomical structure and surgical implantation of the shaped matrix.
  • a simple method of delivering additional autogenous cartilage or bone to the craniofacial skeleton that is site specific and of controlled dimensions would reduce surgical trauma and eliminate the need for allografts or alloplastic prostheses. If one could transplant by means of injection or simple application to the desired site, and cause to engraft large numbers of isolated cells, one could augment the craniofacial osseocartilaginous skeleton with autogenous tissue but without extensive surgery. Furthermore, successfully implanting isolated cells would create the potential for tissue culture augmentation of the cells.
  • Extending tissue engineering techniques to a system whereby the cell- polymer constructs are delivered less invasively and retained at the delivery site has been investigated to expand the applicability of tissue engineering to fields such as plastic surgery.
  • Mixtures of dissociated cells and biocompatible polymers in the form of hydrogels have been used to form cellular tissues and cartilaginous structures which include non-cellular material that will degrade and be removed to leave tissue or cartilage that is histologically and chemically the same as naturally produced tissue or cartilage.
  • Slowly polymerizing, biocompatible, biodegradable hydrogels have been demonstrated to be useful as a means of delivering large numbers of isolated cells into a patient to create an organ equivalent or tissue such as cartilage.
  • the gels appear to promote engraftment and provide three dimensional templates for new cell growth, and the resulting tissue can be similar in composition and histology to naturally occurring tissue.
  • a liquid composition that polymerizes to form a gel support matrix is more easily shaped and molded for custom reconstruction or augmentation.
  • a liquid polymer system can potentially be used for injectable delivery, which would be much less invasive than open implantation.
  • Calcium alginate gels have been proposed as components in a means of delivering large numbers of isolated chondrocytes to promote engraftation and cartilage formation. These initial studies were extended in International Patent Publication No. WO 94/25080 to the formulating of slowly polymerizing calcium alginate gels and to the use of these gels to deliver large numbers of chondrocytes by means of injection, for the purpose of generating new cartilage.
  • Such a composition typically will contain 1% sodium alginate in a hydrogel with insoluble calcium sulfate in an amount of about 200 mg per ml of suspension.
  • a small amount of calcium chloride may be carried over into the composition from the cell suspension, but usually less than 0.1 mg per ml in the final suspension.
  • suspensions have a latent period on the order of an hour, followed by a rapid increase in viscosity to produce a relatively hard, even brittle gel within half an hour of the viscosity increase.
  • hydrogel-cell suspensions described above are not totally satisfactory for use in injection into patients in need thereof.
  • the hydrogel-cell suspension hardens before it can be injected into the patient.
  • Such gels are useful for preparing preformed structures for implantation into patients to repair structural defects of known shape, but require extensive surgery to open up a cavity of sufficient size to receive the preformed structure.
  • some hydrogel-cell suspensions maintain low viscosity until injection into the desired location in the body, but such suspensions assume the shape of the existing cavity or space in the patient. Such gels cannot be used where the defect is absence of a defined structure.
  • this invention provides compositions for injection into an animal comprising a biocompatible polymer which forms a stable, partially hardened hydrogel.
  • the composition is preferably a paste which, when formed into a block in vitro, resists flow under a force equal to the force of gravity.
  • the injectable paste is a suspension made up predominantly of irregularly shaped hydrogel particles, linear dimensions in the range of from 30 microns to 500 microns, where the injectable paste has gel strength of at least 0.1 kgf/cm 2 and the hydrogel in the particles has a gel strength of at least 3 kgf/cm 2 .
  • Such a composition may be prepared by fomiing a friable hydrogel and forcing the hydrogel through an orifice whereby the hydrogel is fractured forming irregularly shaped particles; the resulting composition (containing the particles) will appear as a paste retaining consistency sufficient to separate tissue planes in an animal.
  • the biocompatible polymer in the composition of this invention is alginate, and the composition further comprises a highly soluble salt of a multivalent metal cation, a sparingly soluble salt of a multivalent cation.
  • the highly soluble salt and the sparingly soluble salt may both be calcium salts.
  • the highly soluble salt may be calcium chloride and the sparingly soluble salt may comprise a cation selected from the group consisting of copper, calcium, aluminum, magnesium, strontium, barium, tin, and di-, tri- or tetra-functional organic cations and an anion selected from the group consisting of low molecular weight dicarboxylic acid ions, sulfate and carbonate.
  • the sparingly soluble salt is calcium sulfate and the mixture contains calcium chloride/calcium sulfate in ratio of from 0.001 to 100, more preferably from 0.0075 to 1.0, by weight.
  • the composition contains at least 0.5 % alginate by weight and at least about 0.001 g calcium chloride per gram of alginate.
  • the composition further comprises a sequestrant which competes with alginate for binding of calcium ion, and the sequestrant may comprise phosphate anion.
  • the injectable composition of this invention which comprises a biocompatible polymer forming a hydrogel may also comprise living cells, such as chondrocytes and other cells that form cartilage, osteoblasts and other cells that form bone, muscle cells, fibroblasts, and organ cells. Typically, the cells will be dissociated cells and/or cell aggregates.
  • this invention provides a kit for use in the method containing a biocompatible polymer capable of forming a hydrogel (or the polymer may be provided as an already-formed weakly cross-linked hydrogel) and an orifice through which the hydrogel may be forced, thereby fracturing the weakly cross-linked hydrogel (typically the orifice will be part of a syringe needle or cannula).
  • this invention provides a kit for preparing a partially hardened hydrogel composition suitable for injection into an animal which hydrogel will fully harden in vivo, where the kit contains (1) a biocompatible polymer, said biocompatible polymer being capable of forming a hydrogel upon cross-linking with multivalent cations, (2) a highly soluble salt of a multivalent metal cation, and (3) a sparingly soluble salt of a multivalent cation.
  • the kit contains (1) a polymer which forms a hydrogel upon cross-linking by divalent cations, a preferred polymer being alginate; (2) a fully soluble salt containing a divalent metal cation, a preferred soluble salt being calcium chloride; and (3) a sparingly soluble salt having a cation selected from the group consisting of copper, calcium, aluminum, magnesium, strontium, barium, tin, and di-, tri- or tetra-functional organic cations; and an anion selected from the group consisting of low molecular weight dicarboxylic acids, sulfate ions and carbonate ions, said sparingly soluble salt preferably being calcium sulfate.
  • the kit will provide the components such that upon combination of the components, optionally including a suspension of mammalian cells, the combined components will form within 30 minutes a partially hardened hydrogel suitable for injection, having the polymer at a concentration of 1.5%, the fully soluble salt at a concentration of 1.5 mg/L, and the sparingly soluble salt at a concentration of 15 mg/L, and furtiier wherein said partially hardened hydrogel will not under go substantial change in viscosity for at least 4 hours.
  • the components of the kit may be in separate containers, or two of more of the components may be combined in the kit.
  • the biopolymer and at least one of the salts are in powder form, and in a preferred mode the biopolymer powder and the salt powder are combined in one container. More preferably the sparingly soluble salt and the biopolymer are both in powder form and are combined in one container.
  • the kit further contains a sequestrant which competes with alginate for binding of calcium ion, which may be in a separate container or may be combined with one or more other components.
  • this invention provides method for treating anatomical defects in an animal in need of treatment thereof, the method comprising implanting into the animal at the site of the defect a composition according to this invention.
  • the method for treating anatomical defects in an animal in need of treatment thereof comprises the steps of (1) preparing a biodegradable, biocompatible hydrogel which is partially hardened, the partially hardened hydrogel optionally containing living cells, (2) fracturing the hydrogel by passing the hydrogel through an orifice under pressure to produce a suspension containing hydrogel particles, and (3) implanting the suspension into the animal at the site of the defect, the hydrogel suspension after implantation inducing a fibrotic response by surrounding tissue and vascularization of the implant.
  • the method for treating anatomical defects in an animal in need of treatment thereof comprises the steps of (1) preparing a biocompatible hydrogel comprising a biopolymer or a modified biopolymer, optionally containing living cells, (2) passing the hydrogel through an orifice under pressure to produce a flowable composition having consistency sufficient to divide tissue planes, and (3) implanting the flowable composition into the animal at the site of the defect.
  • the composition used in this method forms a partially hardened hydrogel at room temperature which is suitable for injection into an animal and which, after injection, will fully harden in vivo.
  • the present invention provides a readily available source of cross-linking cations, generally in the form of calcium chloride, at a level sufficient only to initiate and partially cross-link a biocompatible anionic polymer (e.g., alginate) to a thick paste consistency, preferably in approximately 15 minutes. More preferably, alginate is present in an amount sufficient to incorporate all water in the formulation into the loosely cross-linked gel (typically greater than about 0.5% alginate is present in such injectable cell suspensions). Such a formulation will set up quickly for prompt use in an operating theater, while mamtaining good "injectable" consistency for an extended period of time to allow completion of procedures. Preferably, the partially cross-linked hydrogel will maintain this consistency in excess of 24 hours.
  • a biocompatible anionic polymer e.g., alginate
  • the consistency will be relatively stable for a sufficient period to allow the hydrogel to be prepared and marketed in partially cross-linked state.
  • the suspension as injected will have a thick consistency which more easily divides tissues when injected and is less subject to extravasation from the injection site.
  • the invention provides a method for treating an anatomical defect in an animal by implanting, into the animal at the site of the defect, a suspension containing a biodegradable, biocompatible polymer which forms a hydrogel, typically upon cross-linking by multivalent ions, which are preferably in the form of a soluble salt of a multivalent ion, and a sparingly soluble salt of a multivalent ion, these components being combined so that the mixture forms a partially hardened, injectable hydrogel, where the partially hardened hydrogel forms an implant of the desired size and shape in situ and retains that size and shape for a period after implantation, and cells of the animal invade the hydrogel implant to form a fibrous cell mass having substantially the same shape as the hardened hydrogel.
  • Figure 1 shows the time course of gel formation at 25 °C for alginate cross-linked with calcium sulfate powder and calcium chloride/calcium sulfate, respectively.
  • Figure 2 shows the time course of gel formation at 37 °C for alginate cross-linked with calcium sulfate powder and calcium chloride/calcium sulfate, respectively.
  • Figure 3 shows the time course of gel formation at 5°C for alginate cross-linked with calcium sulfate powder and calcium chloride/calcium sulfate, respectively.
  • compositions of this invention provides improved compositions that can be implanted into an animal in tissue engineering applications, as well as methods for implanting such compositions in an animal by injection.
  • the composition of this invention comprises a biocompatible polymer in the form of a hydrogel.
  • the compositions of this invention may be used without addition of living cells to the material to be implanted, in which case the implant will be invaded by cells of the surrounding tissue over time to produce a cellular mass having the shape of the original implant, or living cells may be included in the composition, in order to introduce other cell types to the region in which the composition is implanted by injection.
  • compositions described for this invention can be injected to produce a persistent bulking material that will persist for a duration of sufficient length to produce a practical correction of tissue voids resulting from injury, surgery, or inherited malformation.
  • the composition can be applied through incision or injection and then shaped after application.
  • the injected material will maintain shape, and subsequent fibroblastic proliferation and loose connective tissue invasion will produce a vascularized tissue to correct existing voids and to maintain the hydrogel composition where it is placed by injection.
  • the applied gel material is invaded by loose connective tissue to maintain the volume and shape desired.
  • Gel according to this invention exhibits the property of inciting a fibrotic response.
  • injection of alginate gel into subcutaneous sites promotes an infiltration of loose connective tissue in and around the injected gel fragments. Through this response, connective tissue ultimately occupies a significant proportion of the bulk created upon injection of the gel material.
  • Suitable compositions according to this invention are injectable pastes which typically contain irregularly shaped particles made up of a biocompatible polymer in the form of a hydrogel. The suspension will retain sufficient consistency (viscosity) to divide tissues when injected and to avoid extravasation from the injection site. It is believed that characteristics of the gel suspension which stimulate fibrotic response involve the particle size and that the hydrogel character of the particles is important for both stimulation of the fibrotic response and anchoring the implant in the injection site.
  • the composition of this invention appears to be thixotropic.
  • the hydrogel is partially hardened (weakly cross-linked), and as a result the hydrogel resists deformation up to a point; however, with increasing force, the composition will exhibit fluid behavior.
  • a brittle hydrogel is formed and then fractured to form irregularly shaped particles of the desired dimension, for example by forcing the hydrogel through an orifice of suitable size.
  • the resultant suspension of hydrogel particles will hold its shape against the force of gravity.
  • the suspension forms a paste that may be stacked upon itself to form a mound which will maintain substantially the same shape without other support.
  • the resulting block or mound of paste will resist flow like a dab of toothpaste on a plate, although some rounding of the edges may be expected.
  • the hydrogel of this invention is a friable material which fractures when forced through an orifice such as a syringe needle or cannula.
  • the consistency of the hardened hydrogel may change upon changes in the conditions. For example, increased calcium ion concentration will increase the degree of cross-linking for alginate, increased temperature will increase the cross-linking of PLURONICSTM hydrogel, etc.
  • the partially hardened hydrogel according to this invention is stable, holding its shape against a force equal to or less than the effect of gravity for at least two hours, more preferably for at least twenty-four hours, and frequently for time periods measured in weeks.
  • the fractured hydrogel will be a suspension of irregularly shaped particles whose size is a function of the orifice size and pressure. Typically, size will range from 30 ⁇ m to 500 ⁇ m, preferably from 40 ⁇ m to 300 ⁇ m. Suitable orifice size and injection pressures can be determined by the skilled artisan, and effective particle sizes can be confirmed by monitoring the fibrotic response as described in Example 6.
  • the hydrogel may be allowed to hardened inside the barrel of a syringe, and then exertion of pressure on the syringe plunger will force the composition to flow out of the syringe.
  • the composition may be partially hardened and then forced through a 22 gauge cannula at a rate of 10 ml/min. as a high viscosity fluid without severe damage to any cells that may be included in the composition.
  • the composition After flowing through the cannula the composition has the consistency of POLYTEFTM paste.
  • the composition may be a paste with a measured viscosity of at least 15,000 cPs at 25 °C , and when the composition contains cells, injection of the composition through a 22- gauge cannula at a rate of 10 ml min. will not substantially damage the cells (i.e., viability of the cell population reduced by more than 25 %).
  • Cell persistence and viability in the implant after injection and fibrotic reaction can be assessed using scanning electron microscopy, histology, and quantitative assessment with radioisotopes.
  • the function of the cells can be determined using a combination of the above techniques and functional assays. Studies using labeled glucose as well as studies using protein assays can be performed to quantitate cell mass on the polymer scaffolds. These studies of cell mass can then be correlated with cell functional studies to determine what the appropriate cell mass is.
  • function is defined as synthesis of cartilage matrix components (e.g., proteoglycans, collagens) which can provide appropriate structural support for the surrounding attached tissues.
  • the biopolymer-containing composition of this invention is prepared and used in the form of a hydrogel or an aqueous suspension of hydrogel particles.
  • the hydrogel composition of this invention will contain an aqueous medium, which will usually include one or more pharmaceutically acceptable salts, and optionally other components.
  • the hydrogel may be formed by mixing a solution of alginate (e.g., soluble sodium alginate) with a solution containing multivalent ions in an amount sufficient to initiate cross-linking of the alginate to form a partially hardened hydrogel.
  • the amounts and type of salts may vary, but usually the solutes and the solute concentration will be chosen to avoid undue stress on the animal when the composition is injected into the animal's tissues.
  • the hydrogel also contains living cells
  • the other components of the composition will be compatible with the living cells, preferably the composition will contain factors beneficial to growth and maintenance of the cells.
  • a hydrogel is defined as a substance formed when an organic polymer (natural or synthetic) is cross-linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure which entraps water molecules to form a gel.
  • materials which can be used to form a hydrogel include polysaccharides such as alginate, carageenan, polyphosphazines, and polyacrylates, which are cross-linked ionically, or block copolymers such as PluronicsTM or TetronicsTM polyethylene oxide-polypropylene glycol block copolymers which are crosslinked by temperature or pH, respectively.
  • these polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, and the polymers may contain charged side groups, or a monovalent ionic salt thereof.
  • aqueous solutions such as water, buffered salt solutions, or aqueous alcohol solutions
  • polymers with acidic side groups that can be reacted with cations are poly(phosphazenes), poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, poly (vinyl acetate), and sulfonated polymers, such as sulfonated polystyrene.
  • Copolymers having acidic side groups formed by reaction of acryhc or methacrylic acid and vinyl ether monomers or polymers can also be used.
  • acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and acid
  • the ammonium or quaternary salt of the polymers can also be formed from the backbone nitrogens or pendant imino groups.
  • basic side groups are amino and imino groups.
  • Polyphosphazenes are polymers with backbones consisting of nitrogen and phosphorous separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two side chains ("R").
  • the repeat unit in polyphosphazenes has the general structure (I):
  • the polyphosphazenes suitable for cross-linking have a majority of side chain groups which are acidic and capable of forming salt bridges with dior trivalent cations.
  • Examples of preferred acidic side groups are carboxylic acid groups and sulfonic acid groups.
  • Hydrolytically stable polyphosphazenes are formed of monomers having carboxylic acid side groups that are crosslinked by divalent or trivalent cations such as Ca 2+ or Al 3+ . Polymers can be synthesized that degrade by hydrolysis by incorporating monomers having imidazole, amino acid ester, or glycerol side groups.
  • PCPP polyanionic poly [bis(carboxylatophenoxy)] phosphazene
  • Bioerodible polyphosphazines have at least two differing types of side chains, acidic side groups capable of forming salt bridges with multivalent cations, and side groups that hydrolyze under in vivo conditions, e.g., imidazole groups, amino acid esters, glycerol and glucosyl.
  • bioerodible or biodegradable means a polymer that dissolves or degrades within a period that is acceptable in the desired application (usually in vivo therapy), less than about five years and most preferably less than about one year, once exposed to a physiological solution of pH 6-8 having a temperature of between about 25 °C and 38 °C. Hydrolysis of the side chain results in erosion of the polymer.
  • hydrolyzing side chains are unsubstituted and substituted imidizoles and amino acid esters in which the group is bonded to the phosphorous atom through an amino linkage
  • polyphosphazene polymers in which both R groups are attached in this manner are known as polyaminophosphazenes.
  • polyimidazolephosphazenes some of the "R" groups on the polyphosphazene backbone are imidazole rings, attached to phosphorous in the backbone through a ring nitrogen atom.
  • Other "R” groups can be organic residues that do not participate in hydrolysis, such as methyl phenoxy groups or other groups shown in the scientific paper of Allcock, et al., Macromolecules 10:824-830 (1977).
  • the water-soluble polymer with charged side groups is crosslinked by reacting the polymer with an aqueous solution containing multivalent ions of the opposite charge, either multivalent cations if the polymer has acidic side groups or multivalent anions if the polymer has basic side groups.
  • the preferred cations for cross-linking of the polymers with acidic side groups to form a hydrogel are divalent and trivalent cations such as copper, calcium, aluminum, magnesium, strontium, barium, and tin, although di-, tri- or tetra-functional organic cations such as alkylammonium salts, e.g., R 3 N + - ⁇ ⁇ ⁇ / - + NR 3 can also be used.
  • Aqueous solutions of the salts of these cations are added to the polymers to form soft, highly swollen hydrogels and membranes.
  • concentration of cation or the higher the valence, the greater the degree of cross-linking of the polymer. Concentrations from as low as 0.005 M have been demonstrated to cross-link the polymer. Higher concentrations are limited by the solubility of the salt.
  • the preferred anions for cross-linking of the polymers to form a hydrogel are divalent and trivalent anions such as low molecular weight dicarboxylic acids, for example, terepthalic acid, sulfate ions and carbonate ions.
  • Aqueous solutions of the salts of these anions are added to the polymers to form soft, highly swollen hydrogels and membranes, as described with respect to cations.
  • the biocompatible polymer and the cross- linking agent may be dissolved in any physiologically compatible solvent(s).
  • a common cell culture medium M-119 is use as a representative solvent.
  • a variety of polycations can be used to complex and thereby stabilize the polymer hydrogel into a semi-permeable surface membrane.
  • Examples of materials that can be used include polymers having basic reactive groups such as amine or imine groups, having a preferred molecular weight between 3,000 and 100,000, such as polyethylenimine and polylysine. These are commercially available.
  • One polycation is poly (L-lysine); examples of synthetic polyamines are: polyethyleneimine, poly (vinylamine), and poly (allyl amine). There are also natural polycations such as the polysaccharide, chitosan.
  • Polyanions that can be used to form a semi-permeable membrane by reaction with basic surface groups on the polymer hydrogel include polymers and coplymers of acrylic acid, methacrylic acid, and other derivatives of acrylic acid, polymers with pendant S0 3 H groups such as sulfonated polystyrene, and polystyrene with carboxylic acid groups.
  • Polymers that may be used in implants within the contemplation of this invention also include other natural, synthetic or modified biopolymers which under suitable conditions form hydrogels that are Theologically similar to the hydrogels described herein. Selection of suitable biopolymers is within the skill of the ordinary artisan, in view of the hydrogel characteristics described herein, and suitability may be confirmed based on performance of the polymer in assays and tests described herein. Such polymers must be biocompatible and may be non-biodegradable or biodegradable over a period of days, weeks or even years.
  • Suitable biopolymers include, for example, modified alginates and other modified biopolymers (see, e.g., Putnam A J; Mooney D J (1996), “Tissue engineering using synthetic extracellular matrices,” Nature Medicine, 2(7):824-826, (1996); Mooney, D.J. (1996), “Tissue engineering with biodegradable polymer matrixes,” in Bajpai, Praphulla K (Ed), Proc. South. Biomed. Eng. Conf, 15th, IEEE, NY, 1996; and Wong, W.H., and D.J.
  • the method of this invention involves formation of hydrogel by multivalent cation cross-linking of acidic biopolymers in which the availability of the multivalent cation is controlled by dissolution of a sparingly soluble salt to replenish soluble cation as the soluble cation is absorbed in cross-links.
  • a portion of the multivalent cation is provided by a fully soluble salt and is freely available ("fast" cross-linking ion), while another portion of the multivalent cation necessary for full cross- linking is provided in a sparingly soluble salt (“slow" cross-linking ion).
  • the preferred polymer is alginate for this embodiment; however, the method of this invention could also apply to various acidic polymers, such as the biopolymer K-carrageenan.
  • alginate should be considered representative of any suitable polymer.
  • the preferred multivalent ion is calcium.
  • the method of this invention is described herein using calcium and calcium salts as representative cross-linkers for controlling gelation characteristics and final gel properties using multiple cation sources to supply cross-linking cations, where the cation sources are chosen for disparate solubilities.
  • Other multi-valent ions which perform similarly are, of course, within the contemplation of this invention.
  • the composition provided by this invention preferably also contains a soluble buffering system for the multivalent cation, usually phosphate when the cation is a di- or tri-valent metal ion. Phosphate competes with alginate for the metal, so that cross-linking of the alginate in the composition is forestalled by competition between alginate and phosphate anions for the limited amount of available cation as the components of the composition are mixed.
  • a soluble buffering system for the multivalent cation usually phosphate when the cation is a di- or tri-valent metal ion.
  • Phosphate competes with alginate for the metal, so that cross-linking of the alginate in the composition is forestalled by competition between alginate and phosphate anions for the limited amount of available cation as the components of the composition are mixed.
  • the biocompatible acidic biopolymer alginate is cross-linked by a minor portion of fully-soluble calcium chloride and a major amount of the much-less-soluble calcium sulfate.
  • the composition from which the hydrogel is formed contains phosphate anion in relatively high concentration to buffer the soluble calcium ion concentration and forestall complete cross-linking of the alginate. Once the composition is injected at the desired site, phosphate anion is diluted out by diffusion into the surrounding biological fluids, and the concentration of soluble calcium ion increases locally. As the soluble calcium ion concentration increases, more calcium cross-links are formed in the alginate, and the hydrogel hardens. Similar effects may be obtained for analogous metal ions by buffering with phosphate anion or other similar systems, e.g., biologically compatible sequestrants, which buffer soluble cation concentration in an analogous manner.
  • Alginate is a copolymer of stretches of polymannuronate and polyguluronate obtained from seaweed. Suitable alginate is available from commercial sources. individual alginate preparations will have a determinable capacity for binding calcium which is a function of the mannuronate:guluronate (M/G) ratio. Effects resulting from varying the ratio between mannuronate and guluronate residues are described in U.S. Patent No. 4,950,600, incorporated herein by reference. A suitable, highly purified alginate has M G ration of 35/65.
  • Alginate can be ionically cross-linked with divalent cations, in water, at room temperature, to form a hydrogel matrix. Due to these mild conditions, alginate has been the most commonly used polymer for hybridoma cell encapsulation, as described, for example, in U.S. Patent No. 4,352,883 to Lim.
  • an aqueous solution containing the biological materials to be encapsulated is suspended in a solution of a water soluble polymer, the suspension is formed into droplets which are configured into discrete microcapsules by contact with multivalent cations, then the surface of the microcapsules is crosslinked with polyamino acids to form a semipermeable membrane around the encapsulated materials.
  • Cell/polymer systems in hydrogel form are used for tissue engineering, including suspensions of cells such as chondrocytes in alginate solution to which calcium salts are added to initiate hydrogel formation.
  • chondrocyte/calcium alginate solutions which are created by first vortexing an isolated cell suspension with sodium alginate solution (e.g., in 0.1M K 2 HP0 4 , 0.135 M NaCl, pH 7.4) to yield a cellular density of 20 X 10 6 cells/mL (a cellular density of approximately 50 percent of that of native articular bovine cartilage) in a 1.0% alginate solution.
  • the chondrocyte-sodium alginate suspension may be stored on ice at 4°C until use, and prior to injection, 0.2 gm of sterilized CaS0 4 powder is added to each milliliter of the cold chondrocyte-alginate solution.
  • the present inventors have developed a new formula for injectable hydrogels used in tissue engineering. This formula provides for accelerated gel formation and prolonged injectability of the gel suspension, leading to more consistent performance.
  • this invention provides a hydrogel forming composition containing two sources of cross-linking polyvalent cation: a minor amount of one cation source which provides fully available cation and a major amount of another cation source which provides slow release of the cross-linking ion as the gel is formed.
  • the first cation source is a highly water soluble salt - i.e., solubility of at least lg per 100 ml, preferably at least 30g/ 100ml, more preferably at least 60g/ 100ml.
  • Particularly preferred is a calcium salt such as calcium chloride.
  • the second cation source is a sparingly soluble salt - i.e., solubility less than lg/lOOml, preferably less than 0.5g/100ml, more preferably less than 0.3g/100ml.
  • a calcium salt such as calcium sulfate.
  • the solubilities of calcium sulfate dihydrate (CaS0 4 -2H 2 0) in cold and hot (100°C) water are 2.41 and 2.22 mg/mL, respectively. Any two salts of multivalent cations having similar water solubilities to calcium chloride and calcium sulfate, respectively, are also suitable for use in this invention.
  • Calcium chloride is one preferred "fast" Ca +2 source to speed up the alginate gelling because of its high solubility.
  • Other calcium salts of equivalent solubility work in a similar fashion.
  • Experiments were run to determine if CaCl 2 alone could work. A concentration range of 1.0 to 6.6 mg/mL was tried, and it was found that CaCl 2 alone was not suitable to cross-link the hydrogel, since the alginate gelled up immediately at the interface of alginate and CaCl 2 solutions when the concentration of CaCl 2 -2H 2 0 is equal to or higher than 3.3 mg/mL, but would not gel up at all when equal to or lower than 2.7 mg/mL when alginate was used at a final concentration of 1.5% (w/v).
  • CaCl 2 may range from 0.5mg/mL to 3.0 mg/mL.
  • the amount of CaS0 4 -2H 2 0 required to react stoichiometrically with a typical sodium alginate is 0.309 mg per mg of alginate.
  • a typical known calcium sulfate cross-linked formulation uses 20 mg CaS0 4 -2H 2 0 powder per mg of sodium alginate, or approximately 65 times the amount required.
  • Proportions are preferred which produce a homogeneous gel of acceptable consistency in required time.
  • the preferred ratio of CaS0 4 /CaCl 2 depends on the polymer (e.g., the M/G ratio for alginate), the required time for gelation, required texture strength, etc.
  • the ratio of CaCl 2 .2H 2 0/CaS0 4 .2H 2 0/alginate can be 1: 10: 10, preferably with certain amounts of phosphate present in the formulation.
  • Suitable compositions may have proportions which produce a gel of acceptable consistency in approximately 14 minutes at room temperature.
  • the ratio of CaS0 4 /CaCl 2 which provides about 3 mg calcium chloride and 30 mg of calcium sulfate per 30 mg of alginate is suitable for use with alginate which binds 0.309 g of CaS0 4 -2H 2 0 per g of sodium alginate.
  • the stoichiometry for alginate with a different calcium binding capacity can be readily determined by one skilled in the art, and similar mole ratios of sparingly soluble and freely soluble salts can be calculated to determine suitable amounts of these alternative salts.
  • M G ratio of the alginate determines the Ca-binding capacity.
  • the relative amounts of alginate, fully soluble salt and sparingly soluble salt, and optionally soluble sequestrant will be such that the mixture forms a gel within 20 minutes that will hold its shape against the force of gravity, but may be injected without clogging the injection canula for at least 4 hours. (These times are for incubation of the mixture at room temperature.)
  • formulations using only slowly soluble cation sources produce a partitioning of components into alginate-encapsulated clods of undissolved salt and a more liquid portion that could be collected and injected.
  • Such a product is poorly reproducible in consistency, cannot be well-characterized, well-controlled, or altered to give the final formulation a range of properties.
  • Use of only rapidly soluble cation sources can produce partitioning as well, if the cation cannot be distributed throughout the mixture, as portions of fully cross-linked gel will be produced and are not easily injected. Addition of both a sparingly soluble and a freely available multivalent cation source may circumvent these problems.
  • the hydrogel forming composition according to this invention optionally contains a component which will buffer the amount of cross-linking cation available to the biopolymer.
  • the buffering component is usually an anion sequestrant such as phosphate anion. Rapid and complete cross-linking of the alginate is prevented by the P0 4 anions in the formula competing with alginate in binding of Ca +2 , which greatly reduces the gelation speed. Phosphate anion is typically present at about 0.1M, but the phosphate concentration may be varied from 0.03M to 0.3M to control gelling time.
  • Other biologically compatible sequestrants which will complete with alginate for calcium, and thus prevent formation of alginate encapsulated salt particles in a similar manner, are also contemplated by this invention.
  • the product is homogenous throughout, is produced consistently, can be characterized by conventional testing protocols, is entirely available for application without product loss, and can be adjusted to impart desired properties (e.g. viscosity, gel strength, gelation time, etc). This uniformity in mixing is demonstrated in different mixing formats, such as vortexing or hand mixing in test tubes, magnetic and mechanical stirrers, within mixing syringes, etc.
  • alginate The rate of degradation of alginate is not well documented, and depends, e.g., on the method of cross-linking, type of alginate, and site of administration. Certain formulations of alginate gels are only slowly broken down in the human body due to lack of enzymes that recognize the polysaccharide. Furthermore, alginate can be modified and/or cross-linked with various agents to increase or decrease its rate of degradation. Alginate can be cross-linked using two calcium sources so as to produce a weak gel that can be injected or applied to tissue spaces or voids and be shaped or molded to conform to a desired shape. Production of suitable compositions (except for the addition of cells may be omitted in formulations of the present invention) is described in detail in U.S. Serial No.
  • the present invention produces an enduring tissue-like bulk that maintains its injected dimensions, does not migrate, and which may persist for a period of time significantly greater than current tissue bulking agents.
  • a particularly beneficial characteristic is that the material can be injected through needles of many dimensions, allowing cystoscopic or endoscopic application, with little surgical intervention.
  • compositions of this invention can be used to provide multiple cell types, including genetically altered cells, within a three-dimensional scaffolding for the efficient transfer of large number of cells and the promotion of transplant engraftment for the purpose of creating a new tissue or tissue equivalent. It can also be used for immunoprotection of cell transplants while a new tissue or tissue equivalent is growing by excluding the host immune system.
  • Examples of cells which can be implanted as described herein include chondrocytes and other cells that form cartilage, osteoblasts and other cells that form bone, muscle cells, fibroblasts, and organ cells, and also includes expanded populations of isolated stem cells.
  • organ cells includes hepatocytes, islet cells, cells of intestinal origin, cells derived from the kidney, and other cells acting primarily to synthesize and secret, or to metabolize materials.
  • the cells to be encased in the injectable hydrogel can be obtained directly from a donor, from cell culture of cells from a donor, or from established cell culture lines.
  • cells are obtained directly from a donor, washed and implanted directly in combination with the polymeric material.
  • Cellular material may be dissociated single cells, minced tissue (i.e., clumps of aggregated cells) or cell aggregates generated in vitro from dissociated cells.
  • the cells may be cultured using techniques known to those skilled in the art of tissue culture.
  • Cell persistence and viability after injection can be assessed using scanning electron microscopy, histology, and quantitative assessment with radioisotopes.
  • the function of the implanted cells can be determined using a combination of the above-techniques and functional assays. For example, in the case of hepatocytes, in vivo liver function studies can be performed by placing a cannula into the recipient's common bile duct. Bile can then be collected in increments.
  • Bile pigments can be analyzed by high pressure liquid chromatography looking for underivatized tetrapyrroles or by thin layer chromatography after being converted to azodipyrroles by reaction with diazotized azodipyrroles ethylanthranilate either with or without treatment with P-glucuronidase.
  • Diconjugated and monoconjugated bilirubin can also be determined by thin layer chromatography after alkalinemethanolysis of conjugated bile pigments. In general, as the number of functioning transplanted hepatocytes increases, the levels of conjugated bilirubin will increase. Simple Uver function tests can also be done on blood samples, such as albumin production.
  • Analogous organ function studies can be conducted using techniques known to those skilled in the art, as required to determine the extent of cell function after implantation.
  • islet cells of the pancreas may be delivered in a similar fashion to that specifically used to implant hepatocytes, to achieve glucose regulation by appropriate secretion of insulin to cure diabetes.
  • Other endocrine tissues can also be implanted.
  • Studies using labeled glucose as well as studies using protein assays can be performed to quantitate cell mass on the polymer scaffolds. These studies of cell mass can then be correlated with cell functional studies to determine what the appropriate cell mass is.
  • function is defined as synthesis of cartilage matrix components (e.g., proteoglycans, collagens) which can provide appropriate structural support for the surrounding attached tissues.
  • Precursor cells of chondrocytes can also be used in place of the chondrocytes.
  • Examples are fibroblasts or mesenchymal stem cells which differentiate to form chondrocytes.
  • chondrocytes includes such chondrocyte precursor cells.
  • alginate optionally including the sequestering anion
  • a biodegradable liquid polymer is used, such as alginate which is designed to solidify at a controlled rate upon subsequent mixing with multivalent ionic salts.
  • Variations in the levels of individual components, or conditions of mixing and incubation can be modified to a) control the consistency of the material as injected; b) control the time required for attaining an injectable consistency; c) and controlling the properties of the final gel in vivo to accommodate particular requirements of the receiving tissue site for appropriate texture and dimensional retention.
  • Levels of individual components can be modified to alter different properties of the formulation both before and after application so as to accommodate particular requirements a) for injection and application, b) for successful engraftment of the implant and creation of required properties and function of the final gel and replacement tissue, or c) for the manufacture, distribution, and application to patients of the formulation.
  • injection of a hydrogel formulation into compact tissues e.g. muscle, submucosa
  • compact tissues e.g. muscle, submucosa
  • Alterations of viscosity can be achieved by a number of mechanism either singly or in concert, such as (1) selection of the viscosity of the raw material (e.g.
  • low, medium, or high viscosity alginate low, medium, or high viscosity alginate
  • concentration of gel e.g. a range of 0.3% to 3.0% alginate can be used to achieve a broad range of gel viscosities
  • amount of highly soluble multivalent cation source to control degree of partial cross-linking or (4) level of anions provided to compete with alginate for cation binding.
  • Successful invasion of the implant by different cell types, or the nature of the desired replacement tissue to be created may require alterations of the formulations components. For example, creation of a firm, compact tissue
  • a gel of higher polymer chain length or concentration e.g., >1.5% alginate and/or high guluronic content alginate.
  • Controlling the duration of injectability and properties of a formulation prior to injection would aid the manufacture, distribution, and apphcation of therapies according to this invention.
  • the working time of the final formulation, or the time required for materials to setup to an injectable consistency can be controlled through multiple methods, such as by the amount of highly soluble cation provided and/or the level of anion provided to compete for cation binding, in addition to temperature regulation.
  • duration of an injectable consistency can be controlled through temperature so as to allow a working time of minutes (34-38 °C) or beyond one month (4-8 °C). Temperature plays a very important role in the gel formation speed.
  • the material Upon increasing the temperature, as will occur, for instance, when the material is injected into tissue having a temperature of 37°C, the material will proceed to harden into a fully cross-linked hydrogel.
  • the partially hardened gel could set up in 32 minutes at body temperature and remain injectable for at least 90 minutes.
  • This best case scenario of CaS0 4 at 37 °C still requires excessive time to reach injectable consistency, and is both more complicated and more inconsistent than desired.
  • Cation sources can be chosen to control gelling and gel properties, and also combined to control degradation.
  • the composition according to this invention having both a fast and slow source of cross-linking agent, can provide both more rapid viscosity increase, and a longer time before becoming fully cross-linked compared to the formulation with calcium sulfate alone.
  • the mixture which forms partially hardened hydrogel will also include a significant amount of phosphate anion. Typically, the phosphate concentration will be approximately 0.1 molar. Increasing the concentration of alginate is also helpful for the gel to hold more water, resulting in a thicker paste and a stronger gel, and also in accelerating the gel formation.
  • Preferred alginate level is at least 0.75%, more preferably between 1.5% and 2.5% and up to 3.0%, in the final cell- containing suspension which forms the hydrogel.
  • the acidic biopolymer is sodium alginate
  • the fully soluble salt is calcium chloride
  • the sparingly soluble salt is calcium sulfate.
  • the alginate is present in the amount of at least 0.75% by weight of solution, preferably about 1.5%.
  • the freely soluble salt provides 10 to 15 mM calcium ion, while the sparingly soluble salt is provided as a powder dispersed in the alginate solution in an amount which would supply approximately 8 times more calcium ion if it were completely dissolved.
  • calcium is supplied as the divalent metal cross-linking agent by two salts, calcium chloride and calcium sulfate, in a ratio of 1 part to 10 parts by weight.
  • a suitable cell suspension medium such as M-199
  • 1 part of the same cell suspension medium containing 1.8% anhydrous calcium chloride with 18% calcium sulfate suspended therein is added to the alginate-calcium chloride mixture.
  • the final mixture is mixed thoroughly and used for injection into tissue. A rapid increase in viscosity may be expected within 15 minutes of mixing all of the components together. The consistency of this mixture should be sufficient for the mixture to hold its shape against gravity, but will remain injectable at room temperature for at least 24 hours.
  • a preferred viscosity for injectable application varies by intended use, but is a balance of parameters that include (a) the formulation reservoir (e.g., syringe size, piston diameter, resistance required for proper "touch” or application rate), (b) application device (catheter or needle length, diameter, composition), (c) receiving tissue resistance to division, and (d) type of distribution required (e.g., topical application to bone or organ surface, injection within tissues without extravasation, etc.).
  • the formulation reservoir e.g., syringe size, piston diameter, resistance required for proper "touch” or application rate
  • application device catheter or needle length, diameter, composition
  • receiving tissue resistance to division e.g., topical application to bone or organ surface, injection within tissues without extravasation, etc.
  • kits for use in preparation and injection of the compositions taught herein include the components of the composition in one or more containers and may contain a formulation reservoir (e.g., mixing vessel or syringe) and/or a gel fracture orifice (e.g., cannula or syringe needle).
  • a formulation reservoir e.g., mixing vessel or syringe
  • a gel fracture orifice e.g., cannula or syringe needle
  • hydrogel solution is injected directly into a site in a patient, where the hydrogel forms an implant and induces fibrotic response from the surrounding tissues.
  • the loose connective tissue formed by the fibrotic response holds the hydrogel particles in place, and tissue formation is accompanied by vascularization, producing vascularized mass of soft tissue consistency occupying the volume established during implantation.
  • Such hydrogel implants can be used for a variety of reconstructive procedures, including molding of implants in situ to reconstruct three dimensional tissue defects.
  • cells may be included in the hydrogel composition of the present invention and injected directly into a site in a patient, where the hydrogel hardens into a matrix having cells dispersed therein.
  • cells may be suspended in a biopolymer solution which is poured or injected into a rigid or inflatable mold having a desired anatomical shape, then hardened to form a matrix having cells dispersed therein which can be implanted into a patient. After implantation, the hydrogel ultimately degrades, leaving only the resulting tissue.
  • Such hydrogel-cell mixtures can be used for a variety of reconstructive procedures, including custom molding of cell implants to reconstruct three dimensional tissue defects, filling pre- inserted inflatable molds or scaffolds, as well as implantation of tissues generally. The present invention contemplates such implants using the composition according to this invention.
  • chondrocytes preferably autologous chondrocytes
  • a liquid biodegradable biocompatible polymeric material such as alginate which can be solidified in vivo, or other carrier to form a cell suspension.
  • the hydrogel suspension of this invention may be injected into the area where reflux is occurring, or where a bulking agent is required, in an amount effective to induce formation of tissue bulk that provides the required control over the passage of urine.
  • the suspension contains a biodegradable liquid polymer such as alginate, a copolymer of guluronic and mannuronic acid, which is designed to solidify at a controlled rate when contacted with calcium salts.
  • the hydrogel composition is injected at the desired site where it forms a tissue-like bulk to correct the defect.
  • the hydrogel composition according to this invention may also contain cells such as chondrocytes to supplement the cellular invasion from the surrounding tissue.
  • the cell suspension contains chondrocytes, harvested, grown to confluence, passaged as needed, and then mixed with a biodegradable liquid polymer such as alginate, a copolymer of guluronic and mannuronic acid, which is designed to solidify at a controlled rate when contacted with calcium salts.
  • the cells are mixed with hydrogel forming compositions and then injected at the desired site where they proliferate and correct the defect.
  • Autologous chondrocyte cells are preferred, because with autologous cells, this method of treatment does not require FDA approval.
  • Hydrogel based on weakly cross-linked polymeric material such as alginate
  • a biodegradable polymer serves as a synthetic substrate for the injectable implant for maintenance of tissue architecture in humans.
  • the alginate suspension can be easily injected cystoscopically, and the tissue formed is able to correct vesicoureteral reflux without any evidence of obstruction.
  • the ideal injectable substance for the endoscopic treatment of reflux should be a natural bulking agent which is non-antigenic, non-migratory, and volume stable.
  • the procedure can be performed under 15 minutes, with a short period of a mask anesthetic, in the outpatient unit, without any need for a hospital stay. Neither vesical nor perivesical drainage is required. Since the whole procedure is done endoscopically and the bladder is not entered surgically, there is no postoperative discomfort whatsoever. The patient can return to a normal level of activity almost immediately.
  • the gel material described herein can be formulated from sterile components at a manufacturing site and supplied to a physician either as separate units, which may be combined to form the final gel material, or as a pre-loaded syringe containing the final cross-linked product.
  • This material may be used to replace existing tissue bulking agents; e.g. collagen pastes; Teflon pastes, in applications such as vocal cord paralysis and soft tissue injury voids.
  • x cross-link
  • B block
  • nc no cross-link
  • R.T. room temperature.
  • Blocked needles might have been caused by CaSO4 particles and resulting gel formed around these particles.
  • Each sample contains 1.5 ml 2% Sodium Alginate in pH 7.4 buffer, 1.5 ml Ml 99 Medium (no cells), and indicated amounts of CaSO 4 powder. Materials are stored on ice prior to mixing. After mixing, samples are stored at the indicated temperature, and injected at the indicated time onto mylar sheet.
  • Example 2 Mixtures of Calcium Chloride and Calcium Sulfate.
  • sodium alginate is dissolved in pH 7.4
  • K 2 HP0 4 buffer Cells are supplied in Ml 99 medium and then suspended in the alginate solution. Calcium sulfate powder is stored in a 1.5 ml vial. Calcium chloride is dissolved in M199 medium with concentration of 18 mg/mL and stored in another vial. In the application, the CaC 1 2 solution will be mixed with CaS04 powder, and then mixed with alginate, taken into syringe and wait for about 15 minutes, the formula is ready to be injected.
  • Alginate concentration is 2% by weight/volume
  • CaCl 2 concentration is 18mg/ml in M199 medium
  • Alginate gelled by CaS0 4 powder was prepared as described for Example 1, and alginate gelled by a mixture of CaCl 2 /CaS0 4 was prepared as described for Example 2.
  • the CaCl 2 /CaS0 4 samples were prepared with syringe mixing, and CaS0 4 powder samples were prepared with vortex mixing method. Syringe mixing allows a very simple procedure that is easy to perform and yields a very consistent product. It also permits the use of approved biomedical devices, and creates a closed system to segregate product from environmental exposure. Viscosity changes along the gelling course of the two systems at temperatures of 5 °C, 25 °C and 37°C were measured and the result are plotted in Figure 1 through Figure 3.
  • the CaCl 2 /CaS0 4 sample gelled to an injectable set point 1 at 13 minutes, while the CaS0 4 -only sample did not set the gel until minute 56.
  • the viscosity of the CaCl 2 /CaS0 4 sample before gelling is about 665 cP, and CaS0 4 -only sample is 202 cP; the former is approximately 3.3 times as thick as that of the latter.
  • the alginate starts gelling, its viscosity increases abruptly and reaches very high values (Fig. 1), going from 1100 cP to 30,000 cP in 2 minutes.
  • the viscosity of the CaCl 2 /CaS0 4 sample is about 2 times that of CaS0 4 -only sample (about 40,000 cP vs. 20,000 CP).
  • Injectable set point consistency of gel that can be stacked without collapsing. gels up at 13 minutes. The viscosities before gelling are about 520 and 135 cP respectively for CaCl 2 /CaS0 4 sample and CaS0 4 -only sample at 37°C. The lower initial viscosity is due to the higher temperature. After gelation, the viscosity of the CaCl 2 /CaS0 4 sample could reach 16,600 cP which is approximately 10 times higher than that of CaS0 4 -only formula (Fig. 2), indicating that mixing CaCl 2 and CaS0 4 produces a stronger gel which may permit a better tissue separation in implantation application.
  • Example 6 Experiments conducted to demonstrate a composition of alginate gel having the characteristics of tissue compatibility and injectability.
  • composition was prepared containing the components listed in Table 4 below. This composition had viscosity of approximately 1000 Cp immediately post-mixing. Gelation occurred at approximately 15 minutes post-mixing and produced an intact, but weakly cross-linked gel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur des compostions destinées à être implantées chez un animal et comprenant un polymère biodégradable, biocompatible, qui forme un hydrogel lors de la réticulation. Selon un mode préféré, le polymère est réticulé par des ions multivalents, plus souhaitablement, un sel soluble d'un ion multivalent et un sel modérément soluble d'un ion multivalent, ces composants étant combinés pour obtenir un mélange formant un hydrogel injectable, partiellement durci, la consistance du mélange étant appropriée pour implanter le mélange d'hydrogel partiellement durci chez un animal. Cet hydrogel implanté, partiellement durci, forme in situ un hydrogel totalement durci. De préférence, le mélange contient également un agent séquestrant biocompatible qui rivalise avec le polymère biocompatible dans la liaison de l'ion de réticulation multivalent. Cette composition peut ou peut ne pas contenir de cellules vivantes. L'invention porte également sur des procédés d'implantation de la composition chez un animal, celle-ci pouvant être un implant contenant des cellules vivantes.
EP97953182A 1996-12-10 1997-12-10 Hydrogel ameliore pour la creation de tissu Withdrawn EP0944403A2 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US76273396A 1996-12-10 1996-12-10
US762733 1996-12-10
US5108497P 1997-06-27 1997-06-27
US51084P 1997-06-27
US5955897P 1997-09-19 1997-09-19
US59558P 1997-09-19
PCT/US1997/022859 WO1998025653A2 (fr) 1996-12-10 1997-12-10 Hydrogel ameliore pour la creation de tissu

Publications (1)

Publication Number Publication Date
EP0944403A2 true EP0944403A2 (fr) 1999-09-29

Family

ID=27367902

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97953182A Withdrawn EP0944403A2 (fr) 1996-12-10 1997-12-10 Hydrogel ameliore pour la creation de tissu

Country Status (5)

Country Link
EP (1) EP0944403A2 (fr)
JP (1) JP4002299B2 (fr)
AU (1) AU742316B2 (fr)
CA (1) CA2274661A1 (fr)
WO (1) WO1998025653A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051164A1 (fr) 1998-04-03 1999-10-14 Reprogenesis, Inc. Dispositif de reconstruction des tissus mous et son procede d'utilisation
AU1626500A (en) * 1998-11-16 2000-06-05 Osiris Therapeutics, Inc. Alginate layer system for chondrogenic differentiation of human mesenchymal stemcells
US6761887B1 (en) * 1998-11-16 2004-07-13 Osiris Therapeutics, Inc. Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells
IT1311576B1 (it) * 1999-10-25 2002-03-13 Ghimas Spa Dispositivo medico invasivo, in particolare per la rigenerazionetissutale guidata.
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
JP2009513182A (ja) * 2005-07-21 2009-04-02 エフエムシー バイオポリマー エイエス 急速溶解する生体適合性被覆物で被覆した医療用部材
MX2009008760A (es) 2007-02-21 2009-08-27 Mochida Pharm Co Ltd Composicion para el tratamiento de enfermedades del cartilago.
JP5161482B2 (ja) * 2007-05-09 2013-03-13 オリンパス株式会社 生体組織補填材の製造方法
IL187707A0 (en) * 2007-11-27 2008-11-03 Univ Ben Gurion Alginate scaffold in hepatectomy
US8367637B2 (en) 2008-08-19 2013-02-05 Mochida Pharmaceutical Co., Ltd. Composition for treating arthritic disorder
US9308070B2 (en) 2008-12-15 2016-04-12 Allergan, Inc. Pliable silk medical device
US20110008406A1 (en) 2009-04-20 2011-01-13 Altman Gregory H Silk Fibroin Hydrogels and Uses Thereof
WO2017044896A1 (fr) * 2015-09-09 2017-03-16 Dsm Ip Assets B.V. Compositions d'adhésis et de produits de scellement biomédicaux et leurs procédés d'utilisation
CA3177194A1 (fr) * 2016-04-01 2017-10-05 Boston Scientific Scimed, Inc. Compositions injectables et leurs procedes de preparation et d'utilisation
JP7312822B2 (ja) * 2018-11-06 2023-07-21 ナショナル キャンサー センター 注入型ヒドロゲルシステムおよび病変の標識方法
US20220265831A1 (en) * 2019-08-27 2022-08-25 Crannmed Limited Alginate Based Particles as a Temporary Embolic Agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
JPS63177791A (ja) 1987-01-16 1988-07-21 Kibun Kk 固定化酵素又は固定化微生物の製造法
DE4103876C2 (de) * 1990-02-09 1994-07-07 Asahi Optical Co Ltd Verfahren zur Fixierung einer körnigen Knochen-Prothese und Kit zur Herstellung einer körnigen Knochen-Prothesezusammensetzung zur Verwendung in dem Fixierungsverfahren
NO171069C (no) * 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5658329A (en) * 1995-02-14 1997-08-19 Mentor Corporation Filling material for soft tissue implant prostheses and implants made therewith
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
WO1997017038A1 (fr) * 1995-11-09 1997-05-15 University Of Massachusetts Regeneration de surfaces tissulaires a l'aide de compositions hydrogel-cellules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9825653A2 *

Also Published As

Publication number Publication date
JP2001505809A (ja) 2001-05-08
WO1998025653A2 (fr) 1998-06-18
WO1998025653A3 (fr) 1998-10-15
AU5698698A (en) 1998-07-03
CA2274661A1 (fr) 1998-06-18
AU742316B2 (en) 2001-12-20
JP4002299B2 (ja) 2007-10-31

Similar Documents

Publication Publication Date Title
AU743690B2 (en) Improved hydrogel for tissue engineering
US6730298B2 (en) Tissue formation by injecting a cell-polymeric solution that gels in vivo
JP6762936B2 (ja) 軟骨修復のための移植片足場及びその製造方法
AU742316B2 (en) Improved hydrogel for tissue engineering
JP5367266B2 (ja) 自己ゲル化性アルギネート系及びその使用
US6991652B2 (en) Tissue engineering composite
KR100537907B1 (ko) 약물 전달과 조직 처리를 위한 반-교차침투성 또는교차침투성 중합체
JPH10510736A (ja) 胸部組織強化技術
JP2009101188A (ja) 注入可能な多糖類−細胞組成物
TW200403268A (en) Biodegradable polyurethane/urea compositions
US20090076606A1 (en) Coated medical device
JP2008043782A (ja) 注入可能な多糖類−細胞組成物
WO1999051164A1 (fr) Dispositif de reconstruction des tissus mous et son procede d'utilisation
CN111870739A (zh) 一种多功能改性壳聚糖自愈合水凝胶的制备方法及应用
WO1998025575A2 (fr) Composition d'hydrogel amelioree

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990708

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CURIS, INC.

17Q First examination report despatched

Effective date: 20020225

18D Application deemed to be withdrawn

Effective date: 20020910

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THERAMAT, INC.

D18D Application deemed to be withdrawn (deleted)
17Q First examination report despatched

Effective date: 20020225

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20110405